Stock Track | Veracyte Soars 16.18% on Stellar Q3 Results and Raised 2025 Outlook

Stock Track11-05

Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported better-than-expected revenue and earnings, significantly outperforming analyst estimates and demonstrating strong growth across its key business segments.

Veracyte announced total revenue of $131.9 million for Q3, representing a 14% year-over-year increase and beating analyst estimates of $124.6 million. The company's testing revenue, which accounts for the bulk of its business, grew by an impressive 17% to $127.8 million, fueled by strong demand for its Decipher Prostate and Afirma tests. Earnings per share came in at $0.51, significantly outperforming the analyst consensus estimate of $0.13 and marking a 54.55% increase from the same period last year.

Adding to investor optimism, Veracyte raised its full-year 2025 guidance. The company now expects total revenue between $506 million and $510 million, up from its previous forecast. Additionally, Veracyte increased its adjusted EBITDA guidance to over 25% of revenue, signaling improved profitability. The strong quarterly performance, coupled with the upward revision in guidance, has bolstered investor confidence in Veracyte's growth trajectory and operational execution, leading to the significant stock price appreciation during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140326399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140326399","market":"sg","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 16.18% on Stellar Q3 Results and Raised 2025 Outlook","media":"Stock Track","content":"<p>Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported better-than-expected revenue and earnings, significantly outperforming analyst estimates and demonstrating strong growth across its key business segments.</p>\n\n<p>Veracyte announced total revenue of $131.9 million for Q3, representing a 14% year-over-year increase and beating analyst estimates of $124.6 million. The company's testing revenue, which accounts for the bulk of its business, grew by an impressive 17% to $127.8 million, fueled by strong demand for its Decipher Prostate and Afirma tests. Earnings per share came in at $0.51, significantly outperforming the analyst consensus estimate of $0.13 and marking a 54.55% increase from the same period last year.</p>\n\n<p>Adding to investor optimism, Veracyte raised its full-year 2025 guidance. The company now expects total revenue between $506 million and $510 million, up from its previous forecast. Additionally, Veracyte increased its adjusted EBITDA guidance to over 25% of revenue, signaling improved profitability. The strong quarterly performance, coupled with the upward revision in guidance, has bolstered investor confidence in Veracyte's growth trajectory and operational execution, leading to the significant stock price appreciation during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 16.18% on Stellar Q3 Results and Raised 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 16.18% on Stellar Q3 Results and Raised 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported better-than-expected revenue and earnings, significantly outperforming analyst estimates and demonstrating strong growth across its key business segments.</p>\n\n<p>Veracyte announced total revenue of $131.9 million for Q3, representing a 14% year-over-year increase and beating analyst estimates of $124.6 million. The company's testing revenue, which accounts for the bulk of its business, grew by an impressive 17% to $127.8 million, fueled by strong demand for its Decipher Prostate and Afirma tests. Earnings per share came in at $0.51, significantly outperforming the analyst consensus estimate of $0.13 and marking a 54.55% increase from the same period last year.</p>\n\n<p>Adding to investor optimism, Veracyte raised its full-year 2025 guidance. The company now expects total revenue between $506 million and $510 million, up from its previous forecast. Additionally, Veracyte increased its adjusted EBITDA guidance to over 25% of revenue, signaling improved profitability. The strong quarterly performance, coupled with the upward revision in guidance, has bolstered investor confidence in Veracyte's growth trajectory and operational execution, leading to the significant stock price appreciation during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1140326399","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140326399","pubTimestamp":1762355147,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票追踪|Veracyte因出色的第三季度业绩飙升16.18%并上调2025年展望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported better-than-expected revenue and earnings, significantly outperforming analyst estimates and demonstrating strong growth across its key business segments.\nVeracyte announced total revenue of $131.9 million for Q3, representing a 14% year-over-year increase and beating analyst estimates of $124.6 million. The company's testing revenue, which accounts for the bulk of its business, grew by an impressive 17% to $127.8 million, fueled by strong demand for its Decipher Prostate and Afirma tests. Earnings per share came in at $0.51, significantly outperforming the analyst consensus estimate of $0.13 and marking a 54.55% increase from the same period last year.\nAdding to investor optimism, Veracyte raised its full-year 2025 guidance. The company now expects total revenue between $506 million and $510 million, up from its previous forecast. Additionally, Veracyte increased its adjusted EBITDA guidance to over 25% of revenue, signaling improved profitability. The strong quarterly performance, coupled with the upward revision in guidance, has bolstered investor confidence in Veracyte's growth trajectory and operational execution, leading to the significant stock price appreciation during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140326399","isCrawlerRequest":true}